CA2252696A1 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosis Download PDFInfo
- Publication number
- CA2252696A1 CA2252696A1 CA002252696A CA2252696A CA2252696A1 CA 2252696 A1 CA2252696 A1 CA 2252696A1 CA 002252696 A CA002252696 A CA 002252696A CA 2252696 A CA2252696 A CA 2252696A CA 2252696 A1 CA2252696 A1 CA 2252696A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- fluorophenyl
- compound
- oxoazetidin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP9608646.7 | 1996-04-26 | ||
GBGB9608646.7A GB9608646D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GBGB9623756.5A GB9623756D0 (en) | 1996-11-15 | 1996-11-15 | Novel compounds |
EP9623756.5 | 1996-11-15 | ||
GBGB9625121.0A GB9625121D0 (en) | 1996-12-03 | 1996-12-03 | Novel compounds |
EP9625121.0 | 1996-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2252696A1 true CA2252696A1 (en) | 1997-11-06 |
Family
ID=27268259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002252696A Abandoned CA2252696A1 (en) | 1996-04-26 | 1997-04-15 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0915843A1 (xx) |
JP (1) | JP2000509049A (xx) |
AR (1) | AR006833A1 (xx) |
AU (1) | AU2698697A (xx) |
BR (1) | BR9709196A (xx) |
CA (1) | CA2252696A1 (xx) |
CZ (1) | CZ341098A3 (xx) |
HU (1) | HUP9901359A3 (xx) |
ID (1) | ID16660A (xx) |
IL (1) | IL126696A0 (xx) |
MA (1) | MA26426A1 (xx) |
NO (1) | NO984939L (xx) |
NZ (1) | NZ332476A (xx) |
PE (1) | PE64398A1 (xx) |
PL (1) | PL329530A1 (xx) |
TR (1) | TR199802160T2 (xx) |
WO (1) | WO1997041098A1 (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ304450B6 (cs) | 2000-02-16 | 2014-05-14 | Smithkline Beecham P. L. C. | Pyrimidinový derivát |
DE60206365T2 (de) | 2001-03-28 | 2006-07-06 | Schering Corporation, Kenilworth | Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten |
AR038956A1 (es) * | 2001-05-25 | 2005-02-02 | Schering Corp | Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto |
AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
BRPI0721697A2 (pt) | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
WO2012080497A2 (en) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
BR112014001665A2 (pt) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz |
TW201321382A (zh) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | 化合物 |
KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
UY35276A (es) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
BR112015017397A2 (pt) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | compostos pirimidona bicíclica como inibidores de lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
MX2022005615A (es) | 2019-11-09 | 2022-07-27 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
WO1993000332A1 (en) * | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
TW223059B (xx) * | 1991-07-23 | 1994-05-01 | Schering Corp | |
TW275621B (xx) * | 1992-10-27 | 1996-05-11 | Merck & Co Inc | |
AU5802894A (en) * | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
DE69423436T2 (de) * | 1993-06-25 | 2000-09-07 | Smithkline Beecham Plc | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
ES2159573T3 (es) * | 1993-10-06 | 2001-10-16 | Icos Corp | Acetilhidrolasa del factor activador de plaquetas. |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
JPH11500415A (ja) * | 1994-12-22 | 1999-01-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症治療用置換アゼチジン−2−オン |
WO1996029307A1 (fr) * | 1995-03-23 | 1996-09-26 | Japan Tobacco Inc. | Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase |
AP728A (en) * | 1995-07-01 | 1999-01-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis. |
JP2000505063A (ja) * | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
-
1997
- 1997-04-15 HU HU9901359A patent/HUP9901359A3/hu unknown
- 1997-04-15 CA CA002252696A patent/CA2252696A1/en not_active Abandoned
- 1997-04-15 BR BR9709196A patent/BR9709196A/pt not_active Application Discontinuation
- 1997-04-15 WO PCT/EP1997/001898 patent/WO1997041098A1/en not_active Application Discontinuation
- 1997-04-15 AU AU26986/97A patent/AU2698697A/en not_active Abandoned
- 1997-04-15 PL PL97329530A patent/PL329530A1/xx unknown
- 1997-04-15 EP EP97920699A patent/EP0915843A1/en not_active Withdrawn
- 1997-04-15 CZ CZ983410A patent/CZ341098A3/cs unknown
- 1997-04-15 NZ NZ332476A patent/NZ332476A/en unknown
- 1997-04-15 TR TR1998/02160T patent/TR199802160T2/xx unknown
- 1997-04-15 IL IL12669697A patent/IL126696A0/xx unknown
- 1997-04-15 JP JP9538507A patent/JP2000509049A/ja active Pending
- 1997-04-24 MA MA24565A patent/MA26426A1/fr unknown
- 1997-04-24 AR ARP970101682A patent/AR006833A1/es unknown
- 1997-04-24 PE PE1997000311A patent/PE64398A1/es not_active Application Discontinuation
- 1997-04-25 ID IDP971394A patent/ID16660A/id unknown
-
1998
- 1998-10-23 NO NO984939A patent/NO984939L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP9901359A3 (en) | 2000-03-28 |
HUP9901359A2 (hu) | 1999-08-30 |
MA26426A1 (fr) | 2004-12-20 |
PL329530A1 (en) | 1999-03-29 |
EP0915843A1 (en) | 1999-05-19 |
TR199802160T2 (xx) | 1999-04-21 |
IL126696A0 (en) | 1999-08-17 |
NO984939D0 (no) | 1998-10-23 |
ID16660A (id) | 1997-10-30 |
PE64398A1 (es) | 1999-01-06 |
BR9709196A (pt) | 1999-05-25 |
AR006833A1 (es) | 1999-09-29 |
JP2000509049A (ja) | 2000-07-18 |
WO1997041098A1 (en) | 1997-11-06 |
AU2698697A (en) | 1997-11-19 |
NZ332476A (en) | 2000-06-23 |
CZ341098A3 (cs) | 1999-03-17 |
NO984939L (no) | 1998-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2252696A1 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
US6541491B1 (en) | 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors | |
DE69911980T2 (de) | Pyrimidinonderivate zur behandlung von atheroscleros | |
AU704407B2 (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
US6071899A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
JP2005533757A (ja) | アテローム性動脈硬化症の治療においてlp−pla2阻害剤として用いるためのn−置換ピリジノンおよびピリミジノン誘導体 | |
US5561227A (en) | Process for the stereospecific synthesis of azetidinones | |
JP2005532292A (ja) | 新規化合物 | |
JP2005513012A (ja) | Lp−PLA2阻害剤としてのピリドン、ピリダゾンおよびトリアジノン誘導体 | |
WO1997021676A1 (en) | Azetidinone compounds for the treatment of atherosclerosis | |
EP0869943A1 (en) | Monocyclic beta-lactame derivatives for treatment of atherosclerosis | |
JPS6284082A (ja) | 2−オキソ−1−〔〔(置換スルホニル)アミノ〕カルボニル〕アゼチジン類 | |
CA2225627A1 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
US5461162A (en) | Process of synthesizing n-acyl auxiliaries | |
IE842848L (en) | Producing penems | |
US4382089A (en) | Antibacterial amide compounds, compositions thereof and methods of using them | |
US4427586A (en) | 2-Oxoazetidine derivatives and production thereof | |
US5731431A (en) | Process for preparing 4-substituted azetidinone derivatives | |
JP3790564B2 (ja) | シクロヘキサン誘導体、その製造法および疾患の治療におけるその使用 | |
JPS63188662A (ja) | 新規なβ−ラクタム誘導体の製造方法 | |
KR20000065040A (ko) | 아테롬성동맥경화증치료를위한아제티디논유도체 | |
US4192801A (en) | Novel phosphorane intermediates for use in preparing penem antibiotics | |
MXPA98008924A (en) | Azetidinone derivatives for deeterosclero treatment | |
JPH0316357B2 (xx) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |